Patients who developed > 5% hematogones as a fraction of their MNCs constitute a group with significantly improved survival, irrespective of their primary disease. The Kaplan-Meier estimates of OS and RFS in HG⁺ and HG⁻ patients differentiated with their primary disease. In each group of patients with (A) AML or advanced MDS, (B) ALL, and (C) lymphoma, HG⁺ groups showed significantly better OS and RFS, compared with the HG⁻ group (P < .001 for both).